Systemic lupus erythematosus (SLE) is an autoimmune disease that preferentially afflicts young women. Although considered a connective tissue disease, SLE harms a variety of organ systems, including the skin, joints, kidney and brain. Management of active SLE frequently requires the use of multiple non-specific immunosuppressive and cytotoxic drugs that are associated with toxicities and often have limited efficacy. Recently, we have made the surprising discovery that certain FDA-approved Human Immunodeficiency Virus (HIV) protease inhibitors show promise in a variety of preclinical lupus models. Among these, nelfinavir (brand name Viracept), possesses a relatively benign safety profile in HIV patients and is not likely to be immunosuppressive or cause adverse events in lupus patients. On the strength of both nelfinavir's known safety and our preclinical data demonstrating that nelfinavir acts, in part, as a decoy antigen to quench the pathogenic lupus anti-dsDNA autoantibodies, we propose to assess the safety and preliminary efficacy of nelfinavir as a lupus therapeutic in a pilot feasibility phase IIa clinical trial. We will pre-scren subjects for elevated anti-dsDNA autoantibody titers and incorporate early surrogate efficacy measures into this trial design. These and other innovations will bring a personalized medicine approach to lupus and contribute to the likelihood of the trial's success. Moreover, it has not escaped our notice that the repurposing of an FDA- approved drug into a new indication will facilitate an extremely rapid path into an urgent unmet medical need. The successful completion of this proof-of-concept study will lay the groundwork for a definitive clinical trial.

Public Health Relevance

The pilot feasibility clinical trial outlined in this application will assess the safety and preliminary efficacy of an FDA-approved drug, nelfinavir (brand name Viracept), in lupus. Unlike current lupus therapeutics that are immunosuppressive with serious toxicities, our approach aims to target the underlying disease mechanisms in a non-immunosuppressive manner. If successful, our approach offers an extremely rapid path into clinical service, through the repurposing of nelfinavir into a new and urgent indication.

Agency
National Institute of Health (NIH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AR063929-02
Application #
8688912
Study Section
(AMSC)
Program Officer
Witter, James
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
City
Manhasset
State
NY
Country
United States
Zip Code
11030